Lineage Cell Therapeutics updates COR1 corneal cell therapy program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease
July 13, 2026 8:00 AM EDTCompany Will Host Conference Call Today at 4:30 PM ET / 1:30 PM PT
COR1 Aims to Provide an Off the Shelf Supply of Allogeneic CEnCs for Patients Suffering from Corneal Endothelial Disease Utilizes the Companys AlloSCOPE 5D Manufacturing Process, Featuring Seamless, Bioreactor-based Expansion and Differentiation Proprietary Thaw and Inject (TAI) Formulation Offers an Immediate-use Cryopreserved Product Profile to Facilitate Long-Term Storage Current Purity, Scale and Thaw-and-Inject Formulation Support a Superior Product Profile to Cadaver-Sourced CellsCARLSBAD, Calif.--(BUSINESS... More
